Healing Category
THE HEALER
Body Protection Compound-157
BPC-157 is a stomach-derived peptide that signals tissue to heal faster, especially tendons, ligaments, nerves, and the gut lining, by boosting repair factors and protecting against inflammation and stress.
New to BPC-157?
“I heard BPC-157 helps injuries heal.”
01 · Translate it
Recovery and tissue-repair language is the claim to investigate. It does not establish a human benefit or an appropriate product.
02 · Check status
FDA identifies limited safety information for proposed routes and potential concerns involving immune reactions, peptide impurities, and ingredient characterization.
03 · Read in order
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
BPC stands for Body Protection Compound. It was isolated by a research group in Croatia in the 1990s. The body does not make BPC-157 on its own. It makes a much larger protein found in gastric juice, and BPC-157 is a 15-amino-acid fragment of that parent protein. Interest in gut-derived healing compounds is old: the same Pavlov known for his work with dogs also studied gastric juice as a medicine for digestive complaints. BPC-157 was first explored as a treatment for the gut, and its reputation for tendon and muscle repair came later.
BPC-157 is best known online for tendon, ligament, and muscle recovery, but a lot of the research interest sits in the gut, where it was first studied. People also read about it for general digestive comfort. There is early interest in effects on the gut-brain axis as well, including reports around cravings and mood, though that area is far less studied than its repair effects.
A few things set BPC-157 apart. It has no known receptor, so researchers think it may work by adjusting proteins the body already makes rather than by hitting a single target. It appears to promote repair rather than simply block inflammation, often described as pressing the gas pedal on the body's own healing. In one tendon model it increased the number of growth-hormone receptors on the tissue, which could help the tendon respond to growth signals. In animal studies it also supported healing even when corticosteroids, which usually slow healing, were given at the same time.
BPC-157 is taken either by injection or orally, and the difference matters more than it might seem. Taken orally, it has generally not been detectable in the bloodstream, which suggests it may act locally in the gut rather than travel through the body. Injected BPC-157 does reach the wider system. This is why oral forms are usually associated with gut goals and injectable forms with tendon or muscle goals. This is background, not a recommendation.
One of the odder corners of the BPC-157 literature has nothing to do with tendons. In the mid 2000s the same Croatian group ran a series of experiments on alcohol. In one, mice were given a dose of ethanol high enough to put them fully under: no righting reflex, no reaction to handling, body temperature dropping, and a quarter of the animals did not survive it. The mice given BPC-157 came around faster. A companion study looked at withdrawal instead, and after thirteen days of drinking, animals taken off alcohol abruptly had fewer and milder seizures when given the peptide. Separate rat work found it protected the stomach lining against alcohol damage, which sits much closer to what BPC-157 was originally studied for.
You will see this cited as a hangover fix. It is all rodents, and none of it studied a hangover, which is a different next day problem nobody has put the compound up against. Like most of the BPC-157 literature, it also traces back to one research group. A real and genuinely strange line of research, then, but not a reason to expect anything on a Sunday morning. Fun to know rather than known.
Athletes recovering from sports injuries · People with chronic tendon issues (tennis elbow, Achilles) · Anyone dealing with gut problems (IBS, leaky gut) · Post-surgery recovery · Joint pain and inflammation sufferers
BPC-157 has a long research history, and its tolerability record is a standout. In animal studies no lethal dose has been found even at very high amounts, and it is widely regarded as one of the most well tolerated peptides. Most of the research is in animals, and a large share of that work traces to a single Croatian research group, with some replication by others. Formal human trials are still limited, the main example being a small set of early trials using BPC-157 for a gut condition. That adds up to a compound with an excellent tolerability record and a deep body of animal data, alongside a small amount of formal human research.
BPC-157 has not been approved by the FDA. In late 2024 it was placed on an FDA list that restricts pharmacy compounding, alongside a number of other peptides. It is sometimes sold under the name PDA, short for pentadecapeptide arginate, which is the same compound in a different salt form. It also appears on anti-doping watch lists, so athletes in tested sports should be aware of it.
47 minThe Hunter Williams PodcastThe BPC-157 Masterclass | Complete User's Guide (2026)
Huberman Lab ClipsOrigins & Effects of BPC-157 | Dr. Abud Bakri & Dr. Andrew Huberman
This Is Not Covered - Dr. Ashley FroeseDr Admits - I Was WRONG About The Wolverine Stack
BioavailableBPC-157 Explained: Mechanism, Evidence, Risks, and the Human Trial GapIn-stock prices from 167 vendors, checked Oct 22, 2026.
Market evidence
We found certificates from some of the BPC-157 vendors we track. Based on the certificates our crawler found; vendors may publish more than we index. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.
Certificate assessment
68 evaluated certificates
54 graded · 14 not graded · 19 in the A range.
Each result belongs to the named vendor’s certificate. Grades assess the document and its reported tests, not the vendor’s whole catalog or the safety of a product.
Automated checks can make mistakes. Open “Why this result?” for the reason and any review notice, and check the linked COA’s lot against your product. How grading works
68 evaluated records
Document grade
C3: We couldn't confirm this certificate against the lab's own records, so the grade stops at A-.
Document check: flag.
Lab record: not confirmed.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
BP202026
Document grade
X2: The certificate's identity evidence (Identity (HPLC-RTM) BPC-157 - Confirmed) can't confirm the peptide on its own; that needs mass spectrometry or a side-by-side match to a reference standard.
Document check: fail.
Lab record: not confirmed.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
bpc10-10
Not graded
This checker currently grades injectable peptides. Capsules, sprays and topicals need different safety tests, which we don't grade yet.
Lab record: not confirmed.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
J26AYBPC
Document grade
C10: No endotoxin (bacterial toxin) test is reported, and an injectable needs one, so the grade stops at D.
Document check: flag.
Lab record: not confirmed.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
Document grade
C3: We couldn't confirm this certificate against the lab's own records, so the grade stops at A-.
Document check: flag.
Lab record: not confirmed.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
ZQ-20260805-BPC10-BLUE
Document grade
B2: Identity, purity and amount are supported, and the lab's own records match this certificate.
Document check: flag.
Lab record: matched.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
26082901
Not graded
This looks like one part of a longer certificate (printed page footers show 3/4 and 4/4 indicating this is part of a multi-page report), so it can't be graded on its own. Upload the full certificate of analysis for this batch.
Lab record: not confirmed.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
Not graded
This is an instructional example of a certificate, not an original lab report for a batch. Upload the lab’s original certificate.
Lab record: not confirmed.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
BP08260110A
Document grade
C10: No endotoxin (bacterial toxin) test is reported, and an injectable needs one, so the grade stops at D.
Document check: flag.
Lab record: matched.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
Red Cap
Not graded
This checker currently grades injectable peptides. Capsules, sprays and topicals need different safety tests, which we don't grade yet.
Lab record: not confirmed.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
SBPC0001
| COA grade | Printed lab | Certificate | |||
|---|---|---|---|---|---|
| retaone Lot: BP202026 | Document grade Why this result?C3: We couldn't confirm this certificate against the lab's own records, so the grade stops at A-. Document check: flag. Lab record: not confirmed. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | KOVERA LABS | Oct 6, 2026 | 99.7%99.5%+ | View COA |
| NextGen Peptides Lot: bpc10-10 | Document grade Why this result?X2: The certificate's identity evidence (Identity (HPLC-RTM) BPC-157 - Confirmed) can't confirm the peptide on its own; that needs mass spectrometry or a side-by-side match to a reference standard. Document check: fail. Lab record: not confirmed. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | ILS Laboratories | Sep 23, 2026 | 99.71%99.5%+ | View COA |
| Swiss Chems Lot: J26AYBPC | Not graded Why this result?This checker currently grades injectable peptides. Capsules, sprays and topicals need different safety tests, which we don't grade yet. Lab record: not confirmed. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | Freedom Diagnostics | Sep 23, 2026 | No purity printed | View COA |
| Peptide Partners Lot: Not reported | Document grade Why this result?C10: No endotoxin (bacterial toxin) test is reported, and an injectable needs one, so the grade stops at D. Document check: flag. Lab record: not confirmed. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | TrustPointe Analytics LLC | Sep 9, 2026 | No purity printed | View COA |
| Virtus Peptides Lot: ZQ-20260805-BPC10-BLUE | Document grade Why this result?C3: We couldn't confirm this certificate against the lab's own records, so the grade stops at A-. Document check: flag. Lab record: not confirmed. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | Vanguard Laboratory | Sep 7, 2026 | No purity printed | View COA |
| Prime Peptides Lot: 26082901 | Document grade Why this result?B2: Identity, purity and amount are supported, and the lab's own records match this certificate. Document check: flag. Lab record: matched. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | Freedom Diagnostics | Sep 3, 2026 | 99.63%99.5%+ | View COA |
| Kylo Peptides Lot: Not reported | Not graded Why this result?This looks like one part of a longer certificate (printed page footers show 3/4 and 4/4 indicating this is part of a multi-page report), so it can't be graded on its own. Upload the full certificate of analysis for this batch. Lab record: not confirmed. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | Janoshik Analytical | Aug 27, 2026 | 99.751%99.5%+ | View COA |
| Verified Peptides Lot: BP08260110A | Not graded Why this result?This is an instructional example of a certificate, not an original lab report for a batch. Upload the lab’s original certificate. Lab record: not confirmed. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | Peptide Labs Analytical Solutions | Aug 26, 2026 | 99.376%99.0–99.49% | View COA |
| Nationwide Peptides Lot: Red Cap | Document grade Why this result?C10: No endotoxin (bacterial toxin) test is reported, and an injectable needs one, so the grade stops at D. Document check: flag. Lab record: matched. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | Freedom Diagnostics | Aug 21, 2026 | 99.06%99.0–99.49% | View COA |
| Amino Club Lot: SBPC0001 | Not graded Why this result?This checker currently grades injectable peptides. Capsules, sprays and topicals need different safety tests, which we don't grade yet. Lab record: not confirmed. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | ILS Laboratories | Aug 20, 2026 | 99.67%99.5%+ | View COA |
The clinic network
Request a free connection to a peptide clinic, by telehealth or in person. A licensed clinician decides whether any treatment is right for you. What peptide therapy involves
BPC-157 (Body Protection Compound-157) is a synthetic peptide of 15 amino acids based on a sequence identified in human gastric juice. It is studied in preclinical research for tissue repair and is sold only as a research chemical, not as an approved medicine.
In animal (preclinical) studies, BPC-157 has been investigated for effects on tendon, ligament, muscle, and gut-lining healing and on the formation of new blood vessels (angiogenesis). Its effects in humans have not been established by controlled clinical trials.
No. The U.S. Food and Drug Administration has not approved BPC-157 for any medical use. In 2023, FDA identified BPC-157 as a bulk drug substance with potential safety risks. The Pharmacy Compounding Advisory Committee (PCAC) recommended BPC-157 for the 503A bulks list in July 2026, but a recommendation is not a final rule.
As of this writing, BPC-157 is not on the FDA Section 503A bulk drug substances list. PCAC voted in July 2026 to recommend its inclusion, but a committee recommendation is not a final rule. FDA must complete notice-and-comment rulemaking before BPC-157 can be listed. Until then, it is not a 503A-eligible bulk.
See the research peptide vs compounding pharmacy guideBPC-157 is not a controlled substance in the United States, but it is not an approved drug or dietary supplement either. It is typically sold labeled "for research use only," and its regulatory status varies by country.
Yes. The World Anti-Doping Agency (WADA) lists BPC-157 as a prohibited substance under category S0 (non-approved substances), meaning it is banned at all times for athletes subject to anti-doping testing.
In research settings BPC-157 is usually reconstituted with bacteriostatic water and given by subcutaneous injection, though oral forms have also been studied. No human dose is established, so this is not a dosing recommendation.
Convert a target amount into syringe units with the BPC-157 reconstitution calculatorBPC-157 is frequently discussed alongside TB-500, another peptide studied for recovery in preclinical research. The two are sometimes referenced together, but they are distinct compounds with different sequences and study histories.
See the BPC-157 vs TB-500 comparisonThe Peptide App tracks observed BPC-157 vendor listings by vial size, total price, and price per milligram. Prices reflect what vendors publish and change frequently.
Compare BPC-157 pricesWe don't list specific side effects for BPC-157.
BPC-157 has an editorial safety grade of A (Excellent Safety). BPC-157 has been tested extensively in animals and is considered very safe. No lethal dose (LD50) has ever been established, even at amounts far beyond what anyone would use. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.
The facts do not describe BPC 157's legal status in any specific country. A review states that BPC-157 has no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial. The same review describes BPC-157 as an unapproved peptide sold on the unregulated (illicit) market, and says it lacks an established human safety profile.
According to a review, independent blinded replication, dose-response and therapeutic-window studies, pharmacokinetic/pharmacodynamic characterization, rigorous toxicology, and ultimately controlled human studies would be required before clinical translation of BPC 157 could be considered. The same review concludes that BPC 157 is supported as a hypothesis-generating investigational candidate for further preclinical ischemia-reperfusion injury research rather than as an established therapy.
In animal studies, BPC 157 was reported to support new blood vessel formation (angiogenesis), collagen production (collagen synthesis), fibroblast activity, and modulation of nitric oxide pathways. These effects were described as contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue in those animal studies. In a laboratory study using human arterial tissue, BPC 157 induced concentration-dependent vasorelaxation, predominantly mediated via an endothelium-dependent nitric oxide pathway.
A review of human clinical studies of the reviewed peptides, including BPC-157, found that such studies were limited to a handful of investigations, most lacking robust controls or rigorous study designs. The same review stated that the claimed benefits of emerging peptide supplements, including BPC-157, for musculoskeletal recovery and performance remain unsubstantiated by current human trials.
In in vitro studies using human arteries, endothelial integrity markedly enhanced the maximal vasorelaxation produced by BPC 157. This advantage was largely abolished after NOS inhibition. In human internal mammary artery rings studied in vitro, the NOS inhibitor L-NAME increased contractile responsiveness in intact rings. L-NAME also attenuated BPC 157-induced relaxation in these intact human arterial rings.
BPC-157, also called Bpc-157, is a synthetic pentadecapeptide derived from gastric proteins. It has shown notable reparative and anti-inflammatory properties across diverse preclinical models. A separate study describes it as a gastric pentadecapeptide and investigated its inhibitory potential alongside two newly designed hybrid analogs, CIARA-1 and CIARA-2.
A review states that BPC-157 has no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial. The same review states that no pharmaceutical-grade formulation of BPC-157 has been developed or validated. The review also notes that the peptide lacks BCS classification data, permeability characterization, and formal excipient compatibility studies.
In preclinical animal studies, BPC 157 was reported to support angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways. These effects were described as contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue in those studies. In animal studies, BPC 157 was proposed to protect skeletal muscle against ischemia-reperfusion injury by attenuating oxidative stress, modulating apoptosis, reducing inflammation, and supporting angiogenic activity.
A review states that independent blinded replication, dose-response and therapeutic-window studies, pharmacokinetic/pharmacodynamic characterization, rigorous toxicology, and ultimately controlled human studies would be required before clinical translation of BPC 157 could be considered. The same review describes BPC-157 as an unapproved peptide sold on the unregulated (illicit) market, and states that it lacks an established human safety profile.
In the study, a streamlined analytical workflow was developed to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum and plasma, and BPC-157 was among the compounds detected by this workflow. Sample preparation for this workflow used a single microextraction step with 500 µL of a methanol/water (8:2, v/v) mixture, followed by detection using liquid chromatography coupled with high-resolution mass spectrometry.
In a rat gentamicin nephrotoxicity model, BPC 157 was applied at 10 µg/kg or 10 ng/kg, either in drinking water or daily intraperitoneally. In these rats, BPC 157 counteracted the gentamicin-increased malondialdehyde (MDA) levels in kidney tissue. BPC 157 also counteracted the gentamicin-decreased nitric oxide (NO) and superoxide dismutase (SOD) levels in kidney tissue of these rats.
Yes, in an in vitro study, BPC-157 was described as a reversible competitive acetylcholinesterase (AChE) inhibitor. The study also reported that BPC-157's hybrid analogs act the same way, with enhanced activity seen in structurally modified derivatives. Enzyme kinetics of BPC-157 and its analogs were evaluated in this in vitro work using a modified Ellman assay with Lineweaver-Burk analysis to determine the inhibition parameters.
Promotes new blood vessel growth and reduces inflammation for stubborn injuries.
from $2.60/mg · 170 vendorsNº 005 / 006Anti-inflammatory tripeptide for gut healing and skin
from $1.90/mg · 138 vendorsNº 004 / 006Copper peptide that rebuilds collagen for skin, hair, and healing.
from $0.04/mg · 231 vendorsNº 002 / 006FDA-approved GHRH analog that reduces stubborn visceral fat
from $2.75/mg · 192 vendorsNº 006 / 006Short-acting GH pulse boost timed to your body's natural rhythm
from $2.65/mg · 113 vendorsNº 001 / 006Pure growth hormone boost without the unwanted side effects.
from $1.83/mg · 156 vendorsNº 003 / 006
BPC-157 and TB-500
The Zagreb group behind most BPC-157 papers reports gut, tendon and vascular effects in animals. Independent replication by other labs is scarce.
BPC-157 and TB-500
BPC-157 improved healing in rats by intraperitoneal shot, in drinking water or as a topical cream. No human study has compared routes or injection sites.
BPC-157 and TB-500
BPC-157 improved strength and collagen organization in cut rat Achilles tendons in a 2003 study. Human data are three small pilots, none in tendon patients.
